Early CAR-T Cells expansion is associated with prolonged PFS for patients with RRMM treated with ide-cel: a retrospective monocentric study.

Fiche publication

Date publication

mars 2024

Journal

Transplantation and cellular therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis , Dr CHRETIEN Marie-Lorraine

Tous les auteurs :
Caillot L, Sleiman E, Lafon I, Chretien ML, Gueneau P, Payssot A, Pedri R, Lakomy D, Bailly F, Guy J, Quenot JP, Avet-Loiseau H, Caillot D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38458477

Résumé

The outcome of patients with relapsed and refractory multiple myeloma (RRMM) previously treated with the three main classes of myeloma therapy [immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies] remains poor. Recently, based on the phase II pivotal KarMMa trial [showing prolonged overall survival (OS) and progression-free survival (PFS) among heavily treated patients], idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)- directed chimeric antigen receptor (CAR) T cell therapy has been approved in US for the treatment of RRMM. In France, since June 2021, an early access program has authorized the use of ide-cel in the setting of RRMM (progressive myeloma after at least three previous regimens including the above 3 main anti myeloma therapies).